The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.
Commentary|Articles|May 6, 2026
ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go
Author(s)Ashling Wahner
Fact checked by: Chris Ryan
Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
Preparations for the
Related to this article
Patient-reported QOL and symptom outcomes were similar between belzutifan plus lenvatinib and cabozantinib in previously treated RCC.
The phase 3 DAWN-303 trial is evaluating the oral KRAS G12D inhibitor INCB161734 in previously untreated, KRAS G12D–mutated metastatic PDAC.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The regulatory path to approval for RP1 plus nivolumab in anti–PD-1–pretreated melanoma ran through 3 BLAs, 2 CRLs, and a divided advisory committee vote.
The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.
The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.
Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.
Advertisement
Advertisement